PLUVICTOâ„¢ (lutetium Lu 177 vipivotide tetraxetan) Prostate Cancer Therapy (NDC... Tender

Procurement Summary

Country : USA

Summary : PLUVICTOâ„¢ (lutetium Lu 177 vipivotide tetraxetan) Prostate Cancer Therapy (NDC Code: 69488-0010-61) VA Palo Alto Health care System

Deadline : 10 Jun 2025

Other Information

Notice Type : Tender

TOT Ref.No.: 120328450

Document Ref. No. : 36C26126Q0002

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Login to see details

Tender Details

Description

Special NoticeSpecial NoticePage 3 of 3*= Required FieldPage 1 of 3This notice is published IAW Federal Acquisition Regulation (FAR) Subpart 5.101 requiring posting of information for proposed contract actions. The Department of Veterans Affairs (VA), Network Contracting Office (NCO) 21 intends to award a sole source firm-fixed price contract to Novartis Pharmaceuticals Corporation under the authority of FAR 8.405-6(a)(1)(B), Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized. The North American Industry Classification System (NAICS) for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Federal Supply Class (FSC) is 6505, Drugs and Biologicals. The Small Business Administration (SBA) size standard for this sector is 1, 300 Employees. VA Palo Alto Healthcare System Nuclear Medicine Department has a requirement for Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan), a radioactive therapy treatment for Prostate-specific Membrane Antigen-Positive Metastatic Castration-Resistant Prostate Cancer (PSMA-Positive mCRPC).If your firm provides the radiopharmaceutical therapy on GSA Federal Supply Schedule or any Federal Supply Schedule, please provide applicable contract number and identify which supply/service are applicable to that FSS contract, and the following additional information (1) A tailored capability statement indicating the firm s ability to provide a product and related services; (2) The respondents SAM UEI number, organization name, address, point of contact, and size and type of business (e.g., SDVOSB/VOSB, etc., ) pursuant to the applicable NAICS code; (3) Information should be provided electronically in a Microsoft Word or Adobe PDF format. Potential offerors must be a manufacturer or fully licensed, authorized distributor for the radiopharmaceutical items. Potential offerors must be FDA certified.This ...
Active Contract Opportunity
Notice ID : 36C26126Q0002
Related Notice
Department/Ind. Agency : VETERANS AFFAIRS, DEPARTMENT OF
Sub-tier : VETERANS AFFAIRS, DEPARTMENT OF
Office: 261-NETWORK CONTRACT OFFICE 21 (36C261)
General Information
Contract Opportunity Type: Special Notice (Original)
Original Published Date: Jun 03, 2025 03:45 pm PDT
Original Response Date: Jun 10, 2025 03:00 pm PDT
Inactive Policy: Manual
Original Inactive Date: Aug 09, 2025
Initiative: None

Classification
Original Set Aside:
Product Service Code: 6505 - DRUGS AND BIOLOGICALS
NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing

Place of Performance:

Documents

 Tender Notice